|
|
4 Gatehall Drive, 3rd Floor
Parsippany, NJ 07054 Denmark
phone:973-796-1600
fax:973-796-1666
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.ferringusa.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products in the fields of urology, gynecology, gastroenterology and endocrinology. |
|
| Management |
| Frederik Paulsen, Executive Chairman; Michel L. Pettigrew, Chief Operating Officer; Peter Wilden, CFO; Pascal Danglas, Executive Vice President, Clinical and Product Development; John McGuire, President of the Ferring Research Institutes; Lars Peter Brunse, Executive Vice-President, Technical Operations & Logistics; Joachim Hrig, Senior Vice-President, Global Quality Assurance; Jonathan Grover, Senior Vice-President, Global Information Technology |
| |
|
|
| |
|
| Keywords |
| urology, gynecology, gastroenterology, endocrinology, obstetrics, nasal, sprays, injectables, tablets, ulcerative, colitis, Urology, prostate, urinary, bladder, erectile, cancer, erectile, dysfunction, bbstetrics, infertility |
|
|
|
| Description |
|
Ferring Pharmaceuticals identifies, develops and markets innovative products in the fields of urology, gynecology, gastroenterology and endocrinology. Ferring manufactures products within the company's two main therapeutic areas; namely Urology and Obstetrics. The most important products are Minirin®/DDAVP® (desmopressin) formulations which are produced in different administration forms as nasal sprays, injectables and tablets. |
|
| Products / Services |
The US division of Ferring is the leading provider of gonadotropins for infertility treatment. Products include the foundation of mixed protocol, MENOPUR (menotropins for injection, USP), and its perfect partner, BRAVELLE (urofollitropin for injection, purified). Also, Ferring introduced EUFLEXXA', the first bioengineered injectable hyaluronic acid approved in the US for the treatment of osteoarthritis of the knee.
|
|
|
| Funding |
| Parent company is The Ferring Group, with worldwide annual sales of approximately $1 billion, this global company focuses on 6 therapeutic areas: urology, infertility, obstetrics, gastroenterology, endocrinology, and osteoarthritis. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members